TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25186820
Drug: Propofol-based total
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol-based total intravenous anaesthesia
Study: 9974425
Drug: HRT (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (2 mg estradiol valerate from day 1 to 21 and 1 mg cyproterone acetate from day 12 to 21)
Study: 9974425
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mg/d calcium lactate)
Study: 30012387
Drug: Horticultural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horticultural therapy program (twice/week for 12 sessions)
Study: 22030724
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection (group S): 30 mL of mepivacaine 1.5%
Study: 22030724
Drug: Double injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double injection (group D): 15 mL of mepivacaine 1.5% at the junction of the subclavian artery and the first rib, followed by 15 mL at the lateral aspect of the brachial plexus
Study: 22030724
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection (group S)
Study: 22030724
Drug: Double injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double injection (group D)
Study: 19776178
Drug: S-(-)equol administered
Normalized name: S-equol
DrugBank: Equol (DB11674)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-(-)equol administered as SE5-OH tablets (10 mg)
Study: 19776178
Drug: S-(-)equol administered
Normalized name: S-equol
DrugBank: Equol (DB11674)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-(-)equol administered as SE5-OH tablets (30 mg)
Study: 19776178
Drug: S-(-)equol (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-(-)equol (both doses)
Study: 9440721
Drug: Interferon alfa-2a
Normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa-2a maintenance, 3 million U three times weekly for 1 year
Study: 2570732
Drug: Aspirin 900
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 900 mg b.i.d. for 48 h
Study: 2570732
Drug: Famotidine 2
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 2 mg b.i.d.
Study: 31336766
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no topical antiglaucoma medications)
Study: 15942709
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg lafutidine
Study: 31891605
Drug: D2/D3 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: D2/D3 receptor agonist pramipexole
Study: 23721411
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of gentamicin in combination with metronidazole
Study: 23721411
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of gentamicin in combination with metronidazole
Study: 17926989
Drug: WF10 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: WF10 (0.5 mL/kg body weight/day for five consecutive days, repeated every 3 weeks)
Study: 8707752
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg valaciclovir
Study: 8707752
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL Maalox 65 min after valaciclovir
Study: 8707752
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL Maalox 30 min before valaciclovir
Study: 1602388
Drug: i.v. cocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. cocaine hydrochloride (0, 16 and 32 mg)
Study: 1602388
Drug: smoked cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: smoked cocaine base (0, 25 and 50 mg)
Study: 1602388
Drug: smoked cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: smoked cocaine base (50 mg)
Study: 29912422
Drug: Guided de-escalation
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided de-escalation regimen (1 week prasugrel followed by 1 week clopidogrel and guided maintenance therapy)
Study: 22052104
Drug: Icodextrin 4%
Normalized name: ICODEXTRIN 4% IRRG SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icodextrin 4% solution administered intraperitoneally
Study: 22052104
Drug: Icodextrin 4%
Normalized name: ICODEXTRIN 4% IRRG SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icodextrin 4% solution
Study: 19605605
Drug: Single patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single patient trials (SPTs) for commonly employed treatments in palliative care, specific drugs not mentioned.
Study: 10150322
Drug: Ampicillin/sulbactam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin/sulbactam (2 g/1 g)
Study: 1967947
Drug: Vecuronium 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.01 mg kg‐1 as a priming dose followed by 0.1 mg kg‐1 intubation dose
Study: 1967947
Drug: No priming
Approvals — FDA: no, EMA: no, PMDA: no
Description: No priming dose of vecuronium
Study: 31757262
Drug: 8 mg/day
Normalized name: Neupro 8 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/day galantamine
Study: 31757262
Drug: 16 mg/day
Normalized name: futibatinib 16 mg/day (4 mg x 4) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg/day galantamine
Study: 26138419
Drug: miR‐21‐5p overexpression
Approvals — FDA: no, EMA: no, PMDA: no
Description: miR‐21‐5p overexpression group (adenovirus+0.5 mmol/L H2O2)
Study: 26138419
Drug: H2O2 challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2O2 challenge group (0.5 mmol/L H2O2)
Study: 26138419
Drug: miR‐21‐5p negative
Approvals — FDA: no, EMA: no, PMDA: no
Description: miR‐21‐5p negative transfection group (adenovirus void+0.5 mmol/L H2O2)
Study: 21444867
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment (NAT)
Study: 18667139
Drug: Insulin initiation
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin initiation in patients with T2DM
Study: 15852734
Drug: Chemotherapy or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy or chemoradiation followed by surgery
Study: 11226106
Drug: LR Before
Approvals — FDA: no, EMA: no, PMDA: no
Description: LR Before group (12 mL/kg of LR solution within 20 min before spinal anesthesia)
Study: 11226106
Drug: LR After
Approvals — FDA: no, EMA: no, PMDA: no
Description: LR After group (12 mL/kg of LR solution within 20 min starting immediately after spinal anesthesia)
Study: 11226106
Drug: No Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Infusion group (no LR solution given)
Study: 9692270
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Treatment (CBT) plus disulfiram
Study: 9692270
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Treatment (CBT) plus no medication
Study: 9692270
Drug: Twelve Step
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Twelve Step Facilitation (TSF) plus no medication
Study: 28836796
Drug: Treatment Entry
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Entry Training (TEnT) (4-6 sessions)
Study: 22336488
Drug: Eltrombopag powder
Normalized name: eltrombopag Powder for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag powder for oral suspension (PfOS) 25 mg administered fasted
Study: 2709216
Drug: Diflunisal 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal 1,000 mg administered 30 minutes preoperatively
Study: 2709216
Drug: Diflunisal 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal 1,000 mg administered 30 minutes postoperatively
Study: 75692
Drug: Intra-amniotic hyperosmolar
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-amniotic hyperosmolar urea and 5 mg. of prostaglandin F2alpha (PGF2alpha)
Study: 75692
Drug: Intra-amniotic hyperosmolar
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-amniotic hyperosmolar urea and 10 mg. of prostaglandin F2alpha
Study: 22964475
Drug: Calcium (2
Normalized name: calcium (2ξ)-D-gluco-heptonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (2 g/day) and Vitamin D3 (800 IU/day)
Study: 19997906
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (cognitive-enhancing drug)
Study: 11872516
Drug: Psychoeducational group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational group therapy (up to 18 sessions)
Study: 8682011
Drug: Control (non
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (non fibrinolytic medical therapy)
Study: 2233906
Drug: H. influenzae
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. influenzae type b polysaccharide‐diphtheria toxoid conjugate vaccine (PRP‐D)
Study: 2233906
Drug: H. influenzae
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. influenzae type b polysaccharide‐diphtheria toxoid conjugate vaccine (PRP‐D) after three doses
Study: 582880
Drug: Homatropine methylbromide
Normalized name: Homatropine Methylbromide
DrugBank: Homatropine methylbromide (DB00725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homatropine methylbromide plus phenobarbital in a 20% alcohol solution
Study: 25843243
Drug: 100 kVp
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 kVp with 270 mgI/mL iodixanol
Study: 21252738
Drug: Oxytocin administration
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin administration for 12 hours after membrane rupture
Study: 19723905
Drug: Intravenous epoprostenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous epoprostenol (Flolan)
Study: 15855569
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin (7.5 mg/day)
Study: 15855569
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin (7.5 mg/day) in subgroup with IAA levels > or =80 nU/ml (n = 263)
Study: 15855569
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in subgroup with IAA levels > or =80 nU/ml (n = 263)
Study: 788655
Drug: Antibiotics (Ampicillin)
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotics (Ampicillin)
Study: 27590273
Drug: Directly observed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly observed therapy with fluoxetine
Study: 27590273
Drug: Referral to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral to community mental health treatment
Study: 15606395
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg twice daily for 12 weeks) + Infliximab (5 mg/kg at weeks 6, 8, and 12)
Study: 15606395
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Infliximab (5 mg/kg at weeks 6, 8, and 12)
Study: 15606395
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg twice daily for 12 weeks)
Study: 7505563
Drug: Finasteride, 5
Normalized name: Finasteride, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride, 5 mg for 24 months
Study: 25609176
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide injections (n = 16)
Study: 25609176
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (n = 16)
Study: 16632411
Drug: Natural dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural dietary sources of TFA (milk fat enriched in TFA, approximately 20 g/100 g of total fatty acids)
Study: 10811665
Drug: Protocol-based systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol-based systemic and intrathecal chemotherapy + CNS irradiation (for 36 patients)
Study: 10811665
Drug: LDH levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDH levels greater than 500 IU/L
Study: 1482143
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of fleroxacin alone
Study: 1482143
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of fleroxacin with 1 g of sucralfate every 6 h starting 24 h before and continuing for 48 h after fleroxacin treatment
Study: 30766716
Drug: Follicle stimulating
Normalized name: follicle stimulating hormone
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Follicle stimulating hormone (FSH) level >/= 25.8 mIU/mL
Study: 24803033
Drug: Sodium butyrate
Normalized name: Sodium butyrate
DrugBank: Butyric Acid (DB03568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium butyrate 1 g, 2 g, or 4 g daily
Study: 22030709
Drug: Fluoxetine (n=13)
Normalized name: Ammonia N 13
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (n=13)
Study: 22030709
Drug: Cognitive-Behavior Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavior Therapy (CBT) (n=13)
Study: 20215520
Drug: Pazopanib therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib therapy
Study: 19033112
Drug: 3DCRT at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3DCRT at the total dose of 66 to 70 Gy in 33 to 35 fractions
Study: 19033112
Drug: Stereotactic radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stereotactic radiotherapy (SRT) at the dose of 20 Gy in 4 fractions after 60 Gy 3DCRT
Study: 31503307
Drug: Methotrexate, 25
Normalized name: Methotrexate, 25 mg/mL-NaCl 0.9% preservative-free intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate, 25 mg weekly (n=107)
Study: 31503307
Drug: Mycophenolate mofetil,
Normalized name: Mycophenolate Mofetil, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycophenolate mofetil, 3 g daily (n=109)
Study: 25885521
Drug: ISIS-CRPRx 100
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS-CRPRx 100 mg
Study: 25885521
Drug: ISIS-CRPRx 200
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS-CRPRx 200 mg
Study: 25885521
Drug: ISIS-CRPRx 400
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS-CRPRx 400 mg
Study: 25885521
Drug: ISIS-CRPRx (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS-CRPRx (all doses)
Study: 17184645
Drug: Medium-dose aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medium-dose aspirin (325 mg)
Study: 2123632
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no epoetin beta therapy)
Study: 31999500
Drug: Bauhinia forficata
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bauhinia forficata Link tincture (BFLT) 23.2 mg/mL
Study: 31999500
Drug: Ethanol 81.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 81.20 g/mL
Study: 30643228
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous endotoxin
Study: 30643228
Drug: Baseline activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline activity of glucocorticoid receptor (GR) related TFs
Study: 27592635
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavioral therapy targeting intolerance of uncertainty (CBT‐IU)
Study: 15352909
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein > 6 mg/L
Study: 15352909
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of erythrocyte sedimentation rate and C-reactive protein
Study: 9878986
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tirofiban and heparin
Study: 9878986
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose lamifiban
Study: 9878986
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose lamifiban
Study: 28984076
Drug: Family-Based Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-Based Behavioral Treatment (FBT)
Study: 26316194
Drug: Internet CBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet CBT adjunctive to specialized headache treatment
Study: 26316194
Drug: Specialized headache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialized headache treatment alone
Study: 23746673
Drug: Immediate total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate total provisional prosthesis on temporary immediate implants (test group, 12 patients)
Study: 20213220
Drug: Investigational agents
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational agents
Study: 16373258
Drug: DHEA (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (30 mg/20 mg daily for <45/≥46 years)
Study: 16373258
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups during active treatment
Study: 12027839
Drug: Propofol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (3 mg/kg/h with 5 microg/kg/h remifentanil)
Study: 10204127
Drug: Teicoplanin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (6 mg/kg i.v. single dose)
Study: 10204127
Drug: Cephradine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephradine (1 g i.v. + metronidazole (1 g rectally) with two further doses of cephradine and metronidazole
Study: 2338403
Drug: Piracetam (170
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (170 mg/kg for acute treatment)
Study: 2338403
Drug: Piracetam (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (140 mg/kg/day for chronic treatment)
Study: 30088321
Drug: Pharmacist-led medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led medication review and patient interview upon admission (intervention ED)
Study: 30088321
Drug: Pharmacist-led medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led medication review and patient interview upon admission, medication review during inpatient stay, and medication report and patient counselling at discharge (intervention STAY)
Study: 17936154
Drug: KW-3902 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-3902 2.5 mg
Study: 17936154
Drug: KW-3902 15
Normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-3902 15 mg
Study: 17936154
Drug: KW-3902 30
Normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-3902 30 mg
Study: 17936154
Drug: KW-3902 60
Normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-3902 60 mg
Study: 17936154
Drug: KW-3902 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-3902 (all doses)
Study: 17936154
Drug: KW-3902 10
Normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-3902 10 mg
Study: 15378139
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of atorvastatin daily plus usual therapy
Study: 2628706
Drug: 0.05% metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% metronidazole solution (MD)
Study: 2628706
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution (MDP)
Study: 1104059
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate 1200 mg/day
Study: 27651026
Drug: Buprenorphine (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (0.5, 1, and 3 μg/kg)
Study: 27651026
Drug: Buprenorphine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine plus milnacipran (25 and 50 mg)
Study: 27651026
Drug: Milnacipran (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran (25 or 50 mg)
Study: 27651026
Drug: Milnacipran (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran (50 mg)
Study: 25322262
Drug: Aerobic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerobic and resistance training (50min, moderate intensity, twice a week for 6 weeks)
Study: 22749178
Drug: 379 mg
Normalized name: Razadyne 12 MG (galantamine hydrobromide 15.379 MG) Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 379 mg of Green Tea Extract (GTE)
Study: 19339758
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (walking with simple music)
Study: 10223941
Drug: Rifapentine 600
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifapentine 600 mg oral dose following a high-fat breakfast
Study: 10223941
Drug: Rifapentine 600
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifapentine 600 mg oral dose during fasting
Study: 8582465
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg metoprolol plus 20 mg denopamine
Study: 8582465
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg metoprolol plus denopamine placebo
Study: 2151407
Drug: AH23848 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: AH23848 70 mg
Study: 2151407
Drug: Aspirin 300
Normalized name: aspirin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 300 mg plus dipyridamole 75 mg
Study: 29563108
Drug: blisibimod (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: blisibimod (200 mg weekly)